Sareum Holdings plc

05/13/2021 | Press release | Distributed by Public on 05/13/2021 09:01

Exercise of Options and TVR

SAREUM HOLDINGS PLC

('Sareum' or the 'Company')

Exercise of Options and Total Voting Rights

Sareum Holdings plc (AIM: SAR)announces that it has received notice of exercise of share options from a consultant to the Company over 3,000,000 new ordinary shares of 0.25 pence each in the capital of the Company ('Ordinary Shares') at an exercise price of 0.6 pence per share.

Application has been made to the London Stock Exchange for the 3,000,000 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am 18 May 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 3,270,722,796 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com